8-K current report · filed Oct 28, 2026

ClearPoint Neuro, Inc. (CLPT) 8-K Current Report: October 28, 2026

Item 2.02Item EX-99.1Item EX-99.2Item 7.01CLPT overview

Short answer

ClearPoint Neuro, Inc. (CLPT) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Q3 fiscal 2026 results announced for the quarter ended September 30, 2026.

ClearPoint Neuro, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for the quarter ended September 30, 2026
  • Full financial details and management commentary contained in Exhibit 99.1
  • Results release provides investors the company’s latest quarterly operating and financial update

Item 7.01 · Regulation FD Disclosure

  • Updated investor presentation posted October 28, 2026, signaling refreshed messaging for analysts and investors
  • Presentation available as Exhibit 99.2 and intended for use in future investor communications
  • Investor relevance depends on updated operating, pipeline, or financial information contained in the presentation

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $12.1M, up 36% year over year, with growth outpacing operating-expense growth of 23%
  • Neurosurgery navigation and therapy revenue $5.4M, up 59%, primarily reflecting IRRAflow sales after the IRRAS acquisition
  • Gross margin fell to 58% from 63%, pressured by Advanced Laboratories overhead and acquired-intangible amortization
  • Net loss widened to $7.5M from $5.9M, while interest expense increased to $1.4M from $0.9M
  • 2026 revenue guidance set at $48.0M to $50.0M, supported by $46.2M cash after $22.0M ATM proceeds and $20.1M operating cash use

Item EX-99.2 · Exhibit EX-99.2

  • Investor presentation outlines 2026 strategy, expanding from four to five growth pillars with commercial cell and gene therapy delivery
  • 2026 revenue guidance of $48.0-$50.0 million, versus $37.0 million in 2025
  • Cash and equivalents $46.2 million, with 61% gross margin reported for the quarter ended September 30, 2026
  • Platform scale: 175+ active global centers, 60+ pharma partners, 25+ active clinical trials, and 10+ programs under FDA expedited review
  • Management targets $200 million annual revenue from existing markets and an additional $300 million from 20,000 annual cell and gene therapy procedures

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ClearPoint Neuro, Inc. 8-K filings

Get the next CLPT 8-K as it lands

Follow CLPT for push alerts, or ask the research agent what this filing means.